Monopar Therapeutics (MNPR) Research & Development (2017 - 2026)

Monopar Therapeutics has reported Research & Development for 9 years, with the latest figure at $2.6 million in Q3 2025.

• Quarterly Research & Development rose 163.11% year-over-year to $2.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $7.5 million (up 70.12% YoY) and the FY2024 annual result came in at $4.6 million, changed N/A from the prior year.
• Research & Development grew to $2.6 million in Q3 2025 per MNPR's latest filing, from $1.7 million in the prior quarter.
• Over five years, Research & Development peaked at $2.6 million in Q3 2025 and troughed at $966110.0 in Q1 2024.
• A 5-year average of $1.6 million and a median of $1.6 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2021 and 2024: Research & Development soared 250.39% in 2021, then sank 41.57% in 2024.
• Over 5 years, Research & Development stood at $2.0 million in 2021, then rose by 6.07% to $2.1 million in 2022, then sank by 37.4% to $1.3 million in 2023, then rose by 15.35% to $1.5 million in 2024, then jumped by 70.53% to $2.6 million in 2025.
• According to Business Quant data, Research & Development over the past three periods registered $2.6 million, $1.7 million, and $1.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.